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Cystic epithelial-stromal tumors of the prostate are rare, with 82 cases reported in literature. These cases have been published
under a variety of diagnoses, including phyllodes tumor and prostatic stromal proliferation of uncertain malignant potential as
well as a malignant tumor called “prostatic stromal sarcoma”. We report a case of a 60-year-old man with the histological diagnosis
of phyllodes tumor of the prostate in transurethral resection specimen.
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1.Introduction
Prostatic cystic epithelial-stromal tumors, commonly
described as phyllodes tumors of the prostate, are extremely
rare lesions. They exhibit a spectrum of histological features
similar to their better-known counterpart in the breast.
Although a benign clinical course has been emphasized in
somereports,cumulativeevidenceinliteratureindicatesthat
these lesions should be considered neoplasms rather than
atypical hyperplasia due to the frequent early recurrences
with possible dediﬀerentiation, inﬁltrative growth, and
potential for extraprostatic spread in some cases. An
individualized approach to complete excision of the tumor
is needed. A case report of a patient recently treated in
our hospital is presented, and a review of literature was
done.
2.CaseReport
A 60-year-old man, who visited our hospital, complained of
dysuria and bladder outlet obstruction. Digital rectal exam-
ination revealed a slightly enlarged benign-feeling prostate.
Prostate-speciﬁc antigen was 1.1ng/mL. The urine culture
showed no urinary tract infection. X-ray of the kidneys,
ureters, and bladder was normal, as was renal ultrasound.
Transrectal ultrasound revealed an increased prostate vol-
ume (60mL) without suspicious hypodense or hyperdense
areas. Cystoscopy demonstrated enlarged prostate adenoma
causing bladder outlet obstruction, which was subsequently
resected.
Pathological examination showed a benign prostatic
hyperplasia and features of complex glandular architecture
withaprominentstromalcomponent(Figure 1).Thestroma
consisted of proliferations of elongated and spindle-shaped
cells without cytologic atypia or increased mitotic activity
(Figure 2). Immunostaining for desmin (smooth muscle
marker) and CD34 (mesenchymal marker) conﬁrmed the
diagnosis of a phyllodes tumor of the prostate. Stromal cells
displayed also immunoreactivity for vimentin but moderate
reactivity for actin. Luminal epithelial cells showed intense
immunoreactivity for prostate-speciﬁc antigen. Due to the
absence of necrosis and cellular atypia, this tumor was
classiﬁed as low-grade “indolent” tumor.
Additional staging investigations including X-ray of the
lung and abdominal magnetic resonance imaging revealed
no extracapsular extension of the tumor with absence of
lymph node involvement or metastasis. Sextant biopsies of
the peripheral zone demonstrated normal prostatic tissue.
The patient denied radical surgery, and we performed a
second transurethral resection of the prostate three months2 Journal of Oncology
Figure 1: Phyllodes tumor of the prostate, with leaﬂike protrusions
into a cystic cavity and broad stromal compound (Goldner ×40).
Figure 2: Phyllodes tumor of the prostate: proliferations of
elongated and spindle-shaped cells within the stroma and benign
glandular elements (H & E ×100).
later without further recurrence of the phyllodes tumor. Due
to the malignant potential and the possibility of sarcomatoid
diﬀerentiation of this tumor entity, we perform periodical
close followup every three months in order to be able to
detectandtotreatanyprogressionatanearlystagebyradical
surgical intervention. The patient remains alive and well
without recurrence of the phyllodes tumor after 18 months.
3. Discussion
Phyllodes tumor of the prostate is an uncommon prostatic
neoplasm with distinctive clinical and pathological charac-
teristics.Ithasbeenassignednumerousnamesduringthelast
20 years, including prostatic cystic epithelial-stromal tumor,
phyllodes type of atypical hyperplasia, cystadenoleiomyoﬁ-
broma, prostatic stromal proliferation of uncertain malig-
nant potential, and cystosarcoma phyllodes [1]. The lack
of consistency in the nomenclature reﬂects variability in
the histological appearance and the clinical behavior of this
tumor. Given the similarities with phyllodes tumor of the
breast, the term “phyllodes tumor” seems preferable for this
prostatic lesion. The true incidence is unknown, but the
condition is rare, with around 80 reported cases.
Although the mean age of patients who present with
phyllodes tumors is about 55 years, age range at presentation
from 22 to 86 years and 40% of the patients are younger
than 50 years [2]. The clinical presentation can mimic that
of benign prostatic hyperplasia, with obstruction, dysuria,
hematuria, and urinary retention. The obstructive voiding
symptoms occur at an age younger than expected for typical
prostatic hyperplasia. Additionally, because the tumor often
is large, many patients present with a palpable abdominal
mass [3, 4]. The prostate is palpably enlarged but soft
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may appear lobulated and partially cystic. Diagnosis by
needle biopsy is diﬃcult because the distinctive architectural
features are not well demonstrated. Most cases, like the
demonstrated one, are diagnosed initially after transurethral
resection, and the prostate gland at transurethral resection
is sometimes described as being unusually soft, cystic, or
spongy [5].
Histologically, phyllodes tumor of the prostate is bipha-
sic,consistingofstromalandepithelialcomponentsarranged
to form cysts lined by hyperplastic epithelium. The pro-
liferating stroma is of variable cellularity and sometimes
shows subepithelial condensation. The lining epithelium
is benign, with basal cell and secretory layers that show
immunoreactivity typical of prostatic epithelium, but may
show various metaplastic and proliferative changes such as
basal cell hyperplasia or squamous metaplasia [1]. There is
wide variability in stromal-to-epithelial ratio, stromal cellu-
larity, cytologic atypia, and mitotic activity. These variable
features, as well as the presence or absence of necrosis, have
been quantiﬁed and used to assign a tumor grade. High-
grade “malignant” tumors exhibit greater cellularity, mitotic
ﬁgures, necrosis, and a high stromal-to-epithelial ratio. But
the stratiﬁcation into low, high, and/or even intermediate
grades has not been validated. Certainly grade appears to
be related to outcome in those patients with an overtly
malignant, sarcomatoid component, who are at risk for
extensive local pelvic invasion, distant metastasis, and death.
Metastatic spread is to lungs, bone, and liver. Lymph node
metastases have not been seen.
Tumor recurrence after transurethral resection is com-
mon, occurring in 65% of patients overall, with recurrence
ratesfrom50%forlow-gradetumorsto100%forhigh-grade
tumors [5]. Multiple recurrences are often accompanied by
progressively increasing biological aggressiveness and sarco-
matous transformation. Phyllodes tumors of the prostate
are tumors with a deﬁnite malignant potential. The use of
the term “stromal tumor of uncertain malignant potential”
is discouraged, since this term erroneously encompasses
and lumps together several unique and distinctive tumors—
speciﬁcally phyllodes tumor, low-grade stromal sarcoma,
and prostatic stromal hyperplasia with atypia. These lesions
diﬀer from one another histologically and immunohisto-
chemically, and each requires its own clinical management
strategy [6]. Investigations of gene ampliﬁcations indicate
that epidermal growth factor receptor (EGFR) and androgen
receptor are frequently and strongly expressed in both
epithelial and stromal components of prostatic phyllodes
tumors [7]. Targeted therapy with anti-EGFR and/or antian-
drogen agents might be potentially eﬀective for treatment
of patients with tumors expressing EGFR and/or androgen
receptor in the future.Journal of Oncology 3
Since phyllodes tumor is potentially aggressive, complete
tumor resection propably provides the best chance for cure.
In low-grade tumors alternatively, as in our case, close
cystoscopic and transrectal ultrasound surveillance after 2nd
transurethral resection without further detectable tumor
can achieve local control. However, careful surveillance is
essential as progression to higher grades can occur, requiring
more aggressive intervention.
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